中国骨质疏松杂志

龟鹿二仙胶在骨质疏松症领域研究进展及其现代应用迷思

Progress on Guilu Erxian glue in the treatment of osteoporosis and its modern application confusion

DOI：10.3969/j.issn.1006-7108.2021.09.030

英文关键词:Guilu Erxian glue osteoporosis clinical application fundamental experiments review

基金项目:国家自然科学基金（81973878）；国家自然科学基金（81873320）；无锡市“科教强卫工程”青年人才项目（QNRC042）；南京中医药大学护理学优势学科开放课题（2019YSHL154）；江苏省研究生科研创新计划（KYCX20_1462）

作者	单位
司誉豪1,2 马勇2,3 许奇2 李绍烁2 郭杨2 潘娅岚2 王礼宁2 刘孟敏2 孙杰2 涂鹏程2 吴承杰2 杨光露2 王建伟4 尹恒4*	1.浙江省中医院骨伤科，浙江杭州 310006 2.南京中医药大学骨伤研究所、骨伤修复与重建新技术实验室，江苏南京 210023 3.南京中医药大学中医学院·中西医结合学院，江苏南京 210023 4.南京中医药大学无锡附院骨伤科，江苏无锡 214071

摘要点击次数: 525

全文下载次数: 384

中文摘要:

目前尚无补肾名方龟鹿二仙胶在骨质疏松症领域的系统性总结。本研究整理和分析龟鹿二仙胶相关文献，临床研究发现其能够显著提高患者骨密度，减轻全身骨痛。基础研究认为龟鹿二仙胶能够促进骨形成，抑制骨吸收，改善骨代谢指标，且作用机制可能与调控TGF-β、NF-κB等信号通路有关。然而现有研究存在研究数量少、临证应用方法迥异、细胞干预方式争议的问题，对进一步应用龟鹿二仙胶治疗骨质疏松症造成了阻碍，亟待将来研究重点解决。

英文摘要:

No study has systematically reviewed the application of Guilu Erxian glue (GEG) in the treatment of osteoporosis. The current study collected and analyzed studies related to clinical applications and fundamental experiments regarding GEG. Clinical trials found that GEG could promote bone formation, inhibit bone resorption, and improve bone metabolism outcomes. The potential mechanism is related to the regulation of TGF-β and NF-κB signaling pathways. However, several limitations were discovered, including a lack of study quantity, various clinical use patterns, and debates on the cell-level interventions. Those limitations hinder further applications of GEG in the management of osteoporosis and are requested to be resolved with future study.

查看全文查看/发表评论下载PDF阅读器

关闭